Iterum tests public market's appetite for anti-infectives in $92M IPO
A year ago, the ex-Durata execs at Iterum Therapeutics unveiled a $65 million B round and a Phase III game plan for the antibiotic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
